The effect of raloxifene and tibolone on the uterine blood flow and endometrial thickness: A transvaginal Doppler study

Maturitas

Volumn 53, Issue 3, 2006, Pages 362-368

  Botsis, Dimitrios ^a   Christodoulakos, George ^a   Papagianni, Vassiliki ^a   Lambrinoudaki, Irini ^a   Aravantinos, Leon ^a   Makrakis, Evangelos ^a   Creatsas, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Doppler ultrasonography; Menopause; Raloxifene; Tibolone

Indexed keywords

ESTRADIOL; FOLLITROPIN; RALOXIFENE; TIBOLONE;

ADULT; ARTERY RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER FLOWMETRY; DRUG EFFECT; ENDOMETRIUM; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; RESISTANCE BLOOD VESSEL; TRANSVAGINAL ECHOGRAPHY; UTERINE ARTERY; UTERUS BLOOD FLOW;

ARTERIES; ENDOMETRIUM; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR MODULATORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NORPREGNENES; PROSPECTIVE STUDIES; PULSATILE FLOW; RALOXIFENE; REGIONAL BLOOD FLOW; ULTRASONOGRAPHY, DOPPLER; UTERUS; VASCULAR RESISTANCE;

EID: 31544444131     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.06.010     Document Type: Article

References (49)

1. M. Notelovitz, and J.H. Mattox Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17-beta estadiol Menopause 7 2000 310 317
2. C.B. Hammond Menopause and hormone replacement therapy; an overview Obstet Gynecol 87 Suppl. 2 1996 25 155
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
4. T. Tolbert, and S. Oparil Cardiovascular effects of estrogens Am J Hypertens 14 2001 186S 193S
5. H.D. Nelson, L.L. Humphrey, P. Nygen, S.M. Teutsch, and J.D. Allan Postmenopausal hormone replacement therapy: scientific review JAMA 288 2002 872 881
6. S. Hulley, D. Grady, and T. Bush Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/Progestin Replacement Study (HERS). Research Group JAMA 280 1998 605 613
7. T. Bourne, T. Hillard, D. Crook, and S. Cambell Oestrogens, arterial status, and postmenopausal women Lancet 335 1990 1470 1471
8. M. Penotti, L. Sironi, and E. Castiglioni Blood flow in the internal carotid and middle cerebral arteries: effects of continuous oral conjugated equine estrogens administration with monthly progestogen supplementation on postmenopausal women Menopause 6 3 1999 225 229
9. S. Vyas, and K. Gangar Postmenopausal oestrogens and arteries Br J Obstet Gynaecol 102 1995 942 946
10. C. Exacoustos, S. Lello, and E. Caporale Monitoring of hormone replacement therapy in postmenopausal women by transvaginal sonography and colour flow Doppler study in different phases of sequential therapy Fertil Steril 71 1991 536 543
11. P. Collins, G.M. Rosano, C. Jiang, D. Lindsay, P.M. Sarrel, and P.A. Poole-Wilson Cardiovascular protection by oestrogen - a calcium antagonist effect? Lancet 341 8855 1993 1264 1265
12. A.H. Chester, C. Jiang, J.A. Borland, M.H. Yacoub, and P. Collins Oestrogen relaxes human epicardial coronary arteries through non-endothelium-dependent mechanisms Coron Artery Dis 6 1995 417 422
13. A. Narr, and M. Breckwoldt Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of the iceberg Gynecol Endocrinol 12 1998 43 59
14. V. Mijatovic, M.J. van der Mooren, C.D. Stehouwer, J.C. Netelenbos, and P. Kenemans Postmenopausal hormone replacement risk estimators for coronary artery and cardiovascular protection Gynecol Endocrinol 13 1999 130 144
15. W.M. van Baal, P. Kenemans, and J.J. Emeis Long term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in health postmenopausal women Fertil Steril 71 1999 663 670
16. O. Ylikorkafa, P. Lim, and P. Caubel Effects on serum lipid profiles of continuous combaned 17b-estradiol/norethisterone acetate hormone replacement therapy Clin Ther 22 2000 622 626
17. K. Kojima, S. Abe-Dohmae, R. Arakawa, I. Murakami, K. Suzumori, and S. Yokoyama Progesterone inhibits apolipoprotein-medicated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein Biochim Biophys Acta 1532 2001 173 184
18. I.F. Godsland Effect of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000 Fertil Steril 75 2001 898 915
19. T. Bourne, T.C. Hillard, M.I. Whitehead, D. Crook, and S. Cambell Oestrogens, arterial status and postmenopausal women Lancet 335 1990 1470 1471
20. S.R. Goldstein Selective estrogen receptor modulators: a new category of therapeutic agents for extending the health of postmenopausal women Am J Obstet Gynecol 179 1998 1479 1484
21. S.M. Boss, W.J. Huster, J.A. Neild, M.D. Glant, C.C. Eisenhut, and M.W. Draper Effects of raloxifene hydrochloride on the endometrium of postmenopausal women Am J Obstet Gynecol 177 1997 1458 1464
22. E. Barret-Connor, J.A. Cauley, P.M. Kulkarni, A. Sashegyi, D.A. Cox, and M.J. Geiger Risk-benefit profile for raloxifene: 4 year data from the multiple outcomes of raloxifene evaluation (MORE) randomized trial J Bone Miner Res 19 2004 1270 1275
23. E.E. Jolly, N.H. Bjarnason, and P. Neven Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years Menopause 10 2003 377 441
24. G.C. Davies, W.J. Huster, and W. Shen Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy and unopposed estrogen in postmenopausal women Menopause 6 1999 188 195
25. P. Neven, T. Lunde, and P. Benedetti-Panici A multicenter randomized trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate BJOG 110 2003 157 167
26. F.J. Cohen, S. Watts, A. Shah, R. Akers, and L. Plouffe Jr. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60 Obstet Gynecol 95 2000 104 110
27. S.R. Cummings, S. Eckert, and K.A. Krueger The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial multiple outcomes of raloxifene evaluation JAMA 281 1999 2189 2197
28. B.W. Walsh, S. Paul, and R.A. Wild The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial J Clin Endocrinol Metab 85 2000 214 218
29. E. Barrett-Connor, D. Grady, and A. Sashegyi MORE investigators (multiple outcomes of raloxifene evaluation) raloxifene and cardiovascular events in osteoporotic postmenopausal women. Four year results from the MORE trial JAMA 287 2002 847 857
30. A. Blum, and R.O. Cannon Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and hypercholesterolemic men Ann N Y Acad Sci 949 2001 168 174
31. C.C. Johnston Jr., N.H. Bjarnason, and F.J. Cohen Long-term effects of raloxifene on bone mineral density, bone turnover and serum lipid levels in early postmenopausal women: three year data from 2 double blind randomized placebo-controlled trials Arch Int Med 160 2000 3440 3450
32. B.W. Walsh, L.H. Kuller, and R.A. Wild Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women J Am Med Assoc 279 1998 1445 1451
33. G. Christodoulacos, C. Panoulis, D. Botsis, D. Rizos, D. Kassanos, and G. Creatsas Transvaginal sonographic monitoring of the uterine effects or raloxifene and a continuous combined replacement therapy in postmenopausal women Maturitas 42 2002 77 84
34. A. Chittacharoen, U. Theppisai, and J. Manonai Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy Climacteric 5 2002 156 159
35. G.D. de Azevedo, M.F. do Prado, and R.A. Ferriani Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study Maturitas 47 2004 195 200
36. S.M. Boss, W.J. Huster, J.A. Nelid, M.D. Glant, C.C. Eisenhut, and M.W. Draper Effects of raloxifene hydrochloride on the endometrium of postmenopausal women Am J Obstet Gynecol 177 1997 1458 1464
37. P.D. Delmas, N.H. Bjamason, and B.H. Mitlak Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 337 1997 1641 1647
38. I. Cohen Endometrial pathologies associated with postmenopausal tamoxifen treatment Gynecol Oncol 94 2004 256 266
39. D. de Aloysio, P. Altieri, P. Penacchioni, M. Salgarello, and V. Ventura Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT Maturitas 29 1998 261 264
40. P. Fugere, W.H. Scheele, A. Shah, T.R. Strack, M.D. Glant, and E. Jolly Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women Am J Obstet Gynecol 182 2000 568 574
41. K. Modelska, and S. Cummings Tibolone for postmenopausal women: systematic review of randomized trials J Clin Endocrinol Metabol 87 2002 16 23
42. R. Yazigi, S. Sahid, L. Conteras, and T. Rodriquez Carcinoma of the endometrium in patients treated with tibolone Gynecol Oncol 93 2004 568 570
43. W. Volker, H.J. Coelingh Bennik, and F.A. Helmond Effect of tibolone on the endometrium Climacteric 4 2001 203 208
44. M. Habiba, J. Ramsay, AK.A. Kad, D.M. Hart, and F. al-Azzawi Immunohistochemical and hysteroscopic assessment of postmenopausal women with uterine bleeding whilst taking tibolone Eur J Obstet Gynecol Reprod Biol 66 1996 45 49
45. V. Beral, D. Bull, G Reeves Million Women Study Collaborators Endometrial cancer and hormone-replacement therapy in the Million Women Study Lancet 365 9470 2005 1543 1551
46. C.S. de Vries, S.E. Bromley, H. Thomas, and R.D. Farmer Tibolone and endometrial cancer: a cohort and nested case-control study in the UK Drug Saf 28 2005 241 249
47. M.C. Wender, M.I. Edelweiss, L.S. Campos, J.A. de Castro, and P.M. Spritzer Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study Menopause 11 4 2004 423 429
48. M. Doren, A. Rubig, H.J. Coelingh Bennink, and W. Holzgreve Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy Am J Obstet Gynecol 183 2000 575 582
49. C. Battaglia, F. Mancini, and N. Persico Tibolone, oral or transdermal hormone replacement and colour Doppler analysis: a prospective, randomised pilot study Maturitas 48 2004 446 455